ARKLE RESOURCES PLC

Regulatory Filings • Jan 30, 2024

National Storage Mechanism | Additional information

RNS Number : 3774B

Arkle Resources PLC

30 January 2024

30 January 2024

Arkle Resources PLC

("Arkle" or the "Company")

New licence awarded at Stonepark, Limerick

Arkle (AIM:ARK) announces that the Stonepark zinc project in Limerick ("Stonepark Project"), owned 23.44% by Arkle and 76.56% by Group Eleven Resources Corp. ("Group Eleven"), has been awarded a further prospecting licence, PL3824. The new licence is surrounded by the five licences already held by the joint venture. The interpreted Southwest continuation of the prospective Coonagh Castle Fault underlies the new licence area.

The Group Eleven press release can be found on its website:

https://www.groupelevenresources.com/news/news/2024/

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

Enquiries:

Arkle Resources PLC
John Teeling, Chairman	+353 (0) 1 833 2833
Jim Finn, Finance Director	+353 (0) 1 833 2833
SP Angel Corporate Finance LLP Nominated Adviser & Joint Broker
Matthew Johnson	+44 (0) 203 470 0470
Adam Cowl
Kasia Brzozowska
First Equity Limited
Joint Broker
Jason Robertson	+44 (0) 207 374 2212
BlytheRay	+44 (0) 207 138 3204
Megan Ray
Teneo
Luke Hogg	+353 (0) 1 661 4055
Alan Tyrrell
Fia Long
Alan Reynolds

Information for Editors

Arkle is a diversified exploration company with principal assets in gold, zinc and now lithium exploration licences in Ireland.  The Company currently has two 100% owned gold projects (Mine River and Inishowen) and is in joint venture with Group Eleven Resources Corp. at the Stonepark Zinc Project.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCURRRRSVUAOAR